CASE STUDY
Strategic Combination Therapy in KRAS-Mutant NSCLC: A Preclinical Evaluation Enhanced by Metabolomics
We partnered with Panome Bio to evaluate the combination of an HDAC inhibitor and a MEK inhibitor in a KRAS/LKB1-mutant NSCLC model. Download the full case study to see how our in vivo study design and execution, paired with Panome’s Next-Generation® Metabolomics platform, uncovered key metabolic drivers of synergy in this difficult-to-treat lung cancer subtype.
